Bedrijfsoverzicht
Stereotaxis, Inc. is a specialized manufacturer and marketer of robotic systems, instruments, and information systems designed specifically for use within interventional laboratories across the United States and international markets. The company operates within the healthcare sector, specifically focusing on the medical instruments and supplies industry, which implies a high barrier to entry due to stringent regulatory requirements and significant capital investment in research and development. As of the latest data, the company holds a market capitalization of $182.28 million and employs 131 individuals to support its operations. The annual revenue generated over the trailing twelve months is $32.38 million, indicating that while the company has established a presence in the robotic navigation space, it remains a mid-sized entity within the broader medical device landscape. The combination of a market cap of $182.28 million and revenue of $32.38 million suggests that the market values Stereotaxis at approximately 5.63 times its sales, reflecting investor expectations for future growth that have not yet been fully realized by current profit margins. The employee count of 131 serves as a proxy for the operational scale, suggesting a lean organization that relies heavily on its proprietary robotic magnetic navigation technology, such as the Genesis RMN system, to drive efficiency and market differentiation in the interventional laboratory setting.
Financiële gezondheid
The company reported total revenue of $32.38 million over the trailing twelve months, yet it recorded a net income loss of $22.914 million and an EBITDA loss of $18.386 million. The substantial gap between the positive revenue figure and the significant negative net income reveals a cost structure where expenses, likely driven by high R&D costs, selling, general, and administrative expenses, or depreciation, far exceed gross profits. This discrepancy highlights the operational challenges often faced by growth-stage biotech and medical device firms that prioritize market expansion and product development over immediate profitability. Furthermore, the free cash flow stands at -$6.669 million, indicating a cash burn rate that requires the company to continuously raise capital or utilize existing cash reserves to fund its operations. The balance sheet shows a cash position of $13.42 million against total debt of $5.44 million, resulting in a debt-to-equity ratio of 29.04. Despite the negative earnings, the current ratio of 1.51 indicates that the company possesses adequate short-term assets to cover its short-term liabilities, suggesting a manageable liquidity profile relative to its immediate obligations. However, the return on equity of -143.6% and return on assets of -25.2% clearly demonstrate that the company is currently destroying shareholder value and failing to generate returns on its asset base. These negative return metrics underscore the fact that management has not yet achieved the operational leverage necessary to convert revenue into sustainable profits, a common phase for firms in the medical instruments sector that are still scaling their manufacturing or sales pipelines.
Waarderingsbeoordeling
Stereotaxis, Inc. presents a complex valuation picture with a forward P/E ratio of -15.27 and a trailing P/E ratio listed as N/A due to the lack of net income over the trailing twelve months. The existence of a negative forward P/E implies that the market is pricing in the expectation that earnings will turn positive in the future, while the absence of a trailing P/E reflects the company's current inability to generate profitable earnings. The price-to-book ratio stands at 13.26, indicating that the market values the company at more than thirteen times its book value, which suggests a significant premium assigned to its intangible assets, proprietary technology, and future growth potential despite current losses. Additionally, the price-to-sales ratio is 5.63 and the EV/EBITDA is -9.74, metrics that provide alternative perspectives on valuation when earnings are negative; these figures suggest that investors are willing to pay a high multiple for every dollar of sales, betting on a turnaround in profitability. The stock's price range over the last year spans from a low of $1.67 to a high of $3.59. Without a specific current price provided in the facts to calculate the exact percentage deviation, the metrics establish the volatility envelope within which the stock trades, bounded by these 52-week extremes. The beta value is 1.42, meaning the stock's price volatility is 42% higher than that of the broader market, reflecting the high risk premium associated with small-cap healthcare stocks that have not yet achieved consistent profitability.
Growth & Income
Revenue growth year-over-year is 36.3%, while earnings growth is N/A due to the company's current unprofitability. This divergence indicates that the company is expanding its top line at a rapid pace, but the bottom line has not yet responded proportionately, which is typical for companies in the early stages of commercializing new medical technologies or expanding into new geographic markets. Since the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, meaning the company reinvests all available cash flow back into operations, research, and development rather than distributing income to shareholders. The current reinvestment strategy is necessary to sustain the 36.3% revenue growth and to eventually achieve the profitability required to generate a positive payout ratio in the future. Overall, Stereotaxis, Inc. exhibits a growth-oriented financial profile characterized by strong sales expansion and zero income distribution, prioritizing long-term market penetration and product innovation over short-term shareholder returns.